Evidence map›Paper›PMID 35778541›Full record

ArticleNeurology and therapy2022

Patient Experience in Early-Stage Parkinson's Disease: Using a Mixed Methods Analysis to Identify Which Concepts Are Cardinal for Clinical Trial Outcome Assessment.

Thomas Morel, Sophie Cleanthous, John Andrejack, Roger A Barker, Geraldine Blavat, William Brooks, Paul Burns, Stefan Cano, Casey Gallagher, Lesley Gosden and 6 more

Abstract read
In one paragraph

Article in Neurology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Thomas MorelUCB Pharma SRL, Brussels, Belgium. Thomas.Morel@ucb.com.ORCID http://orcid.org/0000-0002-0690-5359
Sophie CleanthousModus Outcomes, a Division of Thread, London, UK.
John AndrejackPatient Author, Parkinson's Foundation, New York, NY, USA.
Roger A BarkerUniversity of Cambridge, Cambridge, UK.
Geraldine BlavatPatient Author, Parkinson's Foundation, New York, NY, USA.
William BrooksPatient Author, Parkinson's Foundation, New York, NY, USA.
Paul BurnsPatient Author, Parkinson's UK, London, UK.
Stefan CanoModus Outcomes, a Division of Thread, London, UK.
Casey GallagherParkinson's Foundation, New York, NY, USA.
Lesley GosdenPatient Author, Parkinson's UK, London, UK.
Carroll SiuPatient Author, Parkinson's UK, London, UK.
Ashley F SlagleAspen Consulting, LLC, Steamboat Springs, CO, USA.
Kate TrenamUCB Pharma SRL, Brussels, Belgium.
Babak BoroojerdiUCB Biosciences GmbH, Monheim, Germany.
Natasha RatcliffeParkinson's UK, London, UK.
Karlin SchroederParkinson's Foundation, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionQualitative research on patient experiences in early-stage Parkinson's disease (PD) is limited. It is increasingly acknowledged that clinical outcome assessments used in trials do not fully capture the range of symptoms/impacts that are meaningful to people with early-stage PD. We aimed to conceptualize the patient experience in early-stage PD and identify, from the patient perspective, those cardinal symptoms/impacts which might be more useful to measure in clinical trials.

methodsIn a mixed-methods analysis, 50 people with early-stage PD and nine relatives were interviewed. Study design and results interpretation were led by a multidisciplinary group of patient, clinical, regulatory, and outcome measurements experts, and patient organization representatives. Identification of the cardinal concepts was informed by the relative frequency of reported concepts combined with insights from patient experts and movement disorder specialists.

resultsA conceptual model of the patient experience of early-stage PD was developed. Concept elicitation generated 145 unique concepts mapped across motor and non-motor symptoms, function, and impacts. Bradykinesia/slowness (notably in the form of "functional slowness"), tremor, rigidity/stiffness, mobility (particularly fine motor dexterity and subtle gait abnormalities), fatigue, depression, sleep/dreams, and pain were identified as cardinal in early-stage PD. "Functional slowness" (related to discrete tasks involving the upper limbs, complex mobility tasks, and general activities) was deemed to be more relevant than "difficulty" to patients with early-stage PD, who report being slower at completing tasks rather than encountering significant impairment with task completion.

conclusionPatient experiences in early-stage PD are complex and wide-ranging, and the currently available patient-reported outcome (PRO) instruments do not evaluate many early-stage PD concepts such as functional slowness, fine motor skills, and subtle gait abnormalities. The development of a new PRO instrument, created in conjunction with people with PD, that fully assesses symptoms and the experience of living with early-stage PD, is required.

Indexed as

Conceptual modelEarly Parkinson’s diseaseParkinson’s diseasePatient perspectivePatient-reported outcome measures

Identifiers

PMID35778541
PMCPMC9338202

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.